Short answer
Hims & Hers Health, Inc. (HIMS) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $599M (up 49.2% year over year) with net income of $16M.
Q3 2025 key financials · XBRL
- Revenue
- $599M
- +49.2% YoY · +9.9% QoQ
- Net income
- $16M
- −79.1% YoY · −62.9% QoQ
- Operating margin
- 2.0%
- Gross margin
- 73.8%
- EPS (diluted)
- $0.06
- −81.3% YoY · −64.7% QoQ
Source: XBRL data from the Hims & Hers Health, Inc. (HIMS) Q3 2025 10-Q on SEC EDGAR. USD.
Hims & Hers Health, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Constraints on compounded semaglutide supply post FDA shortage resolution May 2025 impacting access and pricing, triggered by evolving GLP-1 regulatory landscape
- Most updated risk: Rapid revenue growth to $1.48B in 2024 with headcount up to 1,637 increases operational strain and requires improved management controls
- Regulatory risk: Increased scrutiny and enforcement on influencer marketing and social media claims with FTC and FDA actions risk fines and reputational damage
- Market risk: Changes in social media platform algorithms and privacy rules, like Meta’s 2025 ad targeting limits, may reduce marketing effectiveness and customer acquisition
- Financial risk: Need for capital to support growth, with risk that acceptable funding may not be available to sustain expansion and marketing investments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Hims & Hers Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.